Clinical Trial Search

Phase 3 N=665 Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine

Opioid Dependence · Opioid Related Disorders

Primary: Cumulative Distribution Function (CDF) of the Percentage of Urine Samples Negative for Opioids Combined With Self-Reports Negative for Illicit Opioid Use Collected From…

Indivior Inc. Results Feb 2018 3.2% serious AE View details

Phase 3 N=687 Efficacy and Safety of Sofosbuvir Plus Ribavirin in Adults With Chronic HCV Infection

Chronic HCV Infection

Primary: Percentage of Participants With Sustained Virologic Response 12 Weeks After Discontinuation of Therapy (SVR12) — 95.5; 100; 100; 94.2 percentage of participants

Gilead Sciences Results Feb 2018 2.3% serious AE View details

Phase 3 N=56 Intra-Articular Injections of Platelet-Rich Plasma in Knee Osteoarthritis: Unique Application Versus Triple Application

Osteoarthritis

Primary: Change in the Western Ontario and McMaster Universities (WOMAC) Ostearthritis Index (Therapeutic Effect) — 28.53; 22.27 units on a scale

Universidad Autonoma de Nuevo Leon Results Feb 2018 0.0% serious AE View details

Phase 3 N=397 Efficacy and Safety of Semaglutide Once-weekly Versus Placebo as add-on to Basal Insulin Alone or Basal Insulin in Combination With Metformin in Subjects With Type 2 Diabetes

Diabetes · Diabetes Mellitus, Type 2

Primary: Change in HbA1c (Glycosylated Haemoglobin) — -1.45; -1.85; -0.09 percentage of glycosylated hemoglobin — p=< 0.0001

Novo Nordisk A/S Results Feb 2018 7.3% serious AE View details

Phase 3 N=1,725 An Open-label, Long-term Safety Study of Linaclotide in Patients With Chronic Constipation or Irritable Bowel Syndrome With Constipation

Irritable Bowel Syndrome With Constipation · Chronic Constipation

Primary: Number of Participants With at Least One Treatment-Emergent Adverse Event (TEAE) — 65; 389; 454 Participants

Ironwood Pharmaceuticals, Inc. Results Feb 2018 5.6% serious AE View details

Phase 3 N=204 A Study on the Use of Tanakan® for Recovery of Neurological Impairment Following Ischaemic Stroke

Stroke, Acute · Neurological Impairment

Primary: Percentage of Subjects With Modified Rankin Score of Less Than 3 at the End of Study Period. — 59.8; 64.7 percentage of participants — p=0.52

Ipsen Results Feb 2018 9.5% serious AE View details

Phase 3 N=210 Safety and Immunogenicity Study of GSK Biologicals' Pandemic Influenza Candidate Vaccine (H1N1) (GSK2340272A)

Influenza

Primary: Number of Subjects With Haemagglutination-inhibition (HI) Antibody Concentrations Above the Cut-off Value — 40 Participants

GlaxoSmithKline Results Feb 2018 0.5% serious AE View details

Phase 3 N=12 A Phase 3 Study of UX003 Recombinant Human Betaglucuronidase (rhGUS) Enzyme Replacement Therapy in Patients With Mucopolysaccharidosis Type 7 (MPS 7)

MPS 7 · Sly Syndrome · Mucopolysaccharidosis

Primary: European Union (EU) and Rest of World: Percentage Change From Baseline in Urinary Glycosaminoglycan (uGAG) Dermatan Sulfate (DS) at UX003 Treatment Week 24 — -64.82…

Ultragenyx Pharmaceutical Inc Results Feb 2018 9.5% serious AE View details

Phase 3 N=92 Optimizing Protein Intake in Older Americans With Mobility Limitations

Mobility Limitation

Primary: Change in Lean Body Mass as Measured by Dual Energy X-ray Absorptiometry (DXA) — 0.14; 0.74; 4.43; 4.13 kg

Brigham and Women's Hospital Results Feb 2018 5.4% serious AE View details

Phase 3 N=40 Rifaximin Associated With Classic Triple Therapy for the Eradication of Helicobacter Pylori Infection

Bacterial Infection Due to Helicobacter Pylori (H. Pylori)

Primary: Percentage of Participants With H.Pylori Infection Eradication — 61 percentage of participants

Fundación de Investigación Biomédica - Hospital… Results Feb 2018 0.0% serious AE View details

Phase 3 N=184 Clinical Study to Investigate the Efficacy and Safety of Two Dose Levels of NT 201 Versus Placebo in Treating Chronic Troublesome Sialorrhea in Various Neurological Conditions

Chronic Troublesome Sialorrhea · Parkinson's Disease · Post-stroke

Primary: MP: Change From Baseline in Unstimulated Salivary Flow (uSFR) Rate at Week 4 — -0.04; -0.06; -0.13 gram per minute (g/min) — p== 0.004

Merz Pharmaceuticals GmbH Results Feb 2018 13.2% serious AE View details

Phase 3 N=27,564 Further Cardiovascular Outcomes Research With PCSK9 Inhibition in Subjects With Elevated Risk

Dyslipidemia

Primary: Time to Cardiovascular Death, Myocardial Infarction, Hospitalization for Unstable Angina, Stroke, or Coronary Revascularization — 3.11; 2.74; 6.01; 5.31 percentage of…

Amgen Results Feb 2018 24.8% serious AE View details

Phase 3 N=219 Evaluation of N1539 Following Abdominoplasty Surgery

Pain, Post-operative

Primary: Summed Pain Intensity Difference Over the First 24 Hours (SPID24) — -4262.1; -3535.7 units on a scale — p=0.0145

Baudax Bio Results Feb 2018 1.8% serious AE View details

Phase 3 N=1,501 Chemotherapy With or Without Bevacizumab in Treating Patients With Stage IB, Stage II, or Stage IIIA Non-small Cell Lung Cancer That Was Removed By Surgery

Stage IB Lung Non-Small Cell Carcinoma AJCC v7 · Stage IIA Lung Non-Small Cell Carcinoma AJCC v7 · Stage IIB Lung Non-Small Cell Carcinoma AJCC v7

Primary: Overall Survival — NA; 85.8 months — p=0.90

National Cancer Institute (NCI) Results Feb 2018 67.0% serious AE View details

Phase 3 N=365 Safety and Efficacy of ZP-Zolmitriptan Intracutaneous Microneedle Systems for the Acute Treatment of Migraine

Acute Migraine

Primary: Proportion of Subjects With Pain Freedom — 11; 24; 23; 34 Participants

Zosano Pharma Corporation Results Feb 2018 0.0% serious AE View details